Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC)
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
Sponsor: Cell Medica Ltd
Terminated
Insufficient recruitment rate
Other terminated trials from Cell Medica Ltd
More terminations from Cell Medica Ltd
Other Hodgkin Lymphoma trials with similar outcome
Listed as NCT02763254, this PHASE2 trial focuses on Hodgkin Lymphoma and Lymphoma, Large B-Cell, Diffuse and remains terminated or withdrawn. Sponsored by Cell Medica Ltd, it has been updated 11 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Feb 2019 — Apr 2019 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Apr 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cell Medica Ltd
For direct contact, visit the study record on ClinicalTrials.gov .